Efficacy and safety of Romosozumab in treatment for low bone mineral density:a systematic review and meta-analysis

Kaveh, Sara, Hosseinifard, Hossein, Ghadimi, Nashmil, Vojdanian, Mahdi and Aryankhesal, Aidin ORCID: https://orcid.org/0000-0002-6695-227X (2020) Efficacy and safety of Romosozumab in treatment for low bone mineral density:a systematic review and meta-analysis. Clinical Rheumatology, 39 (11). pp. 3261-3276. ISSN 0770-3198

Full text not available from this repository. (Request a copy)


Osteoporosis is a chronic skeletal disease with an increasing prevalence. Romosozumab, as a monoclonal anti-sclerostin antibody with a dual function, has been produced. In this meta-analysis, we aimed to examine the efficacy of Romosozumab in patients with low bone mineral density. A systematic search was conducted in the most important electronic search engines like Cochrane Library, PubMed, Web of Science, Scopus, Google Scholar, and ClinicalTrials.gov at the end of July 2019 to retrieve randomized controlled trials (RCTs), which evaluated the effect of Romosozumab in patients with osteoporosis and/or low bone mineral density. After evaluating the quality of articles with the Cochrane checklist, data related to the outcomes of bone mineral density (BMD) of lumbar spine, femoral neck, and total hip, risk of clinical, vertebral and non-vertebral fractures, and risk of adverse events were extracted. Quality of evidence was assessed according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Heterogeneity between studies was evaluated by I2 and Q statistics. The meta-analysis was performed using CMA v.2.0 software. Of all the 671 initially retrieved articles, seven articles were entered into the meta-analysis after removing duplicates and reviewing papers with inclusion and exclusion criteria. The results of the meta-analysis showed that Romosozumab 210, 140, and 70 mg compared with Alendronate, Teriparatide, and placebo can increase the bone mineral density in the lumbar spine, femoral neck, and total hip. The risk of adverse events like adjudicated cardiovascular serious adverse events and adjudicated cardiovascular death was more in Romosozumab 210 mg in comparison with placebo. However, this difference was not statistically significant. Treatment with anti-sclerostin antibodies can be a proper therapeutic option in patients with osteoporosis and low bone mineral density. Based on the results of this meta-analysis, it seems that Romosozumab, with its dual function, has a positive role in the treatment of osteoporosis and low bone mineral density.

Item Type: Article
Additional Information: Funding Information: This research was supported by grant no. [Code: 31150–163–02-96] from Iran University of Medical Sciences. Acknowledgments Publisher Copyright: © 2020, International League of Associations for Rheumatology (ILAR).
Uncontrolled Keywords: amg 785,bone diseases,meta-analysis,osteoporosis,rheumatology ,/dk/atira/pure/subjectarea/asjc/2700/2745
Faculty \ School: Faculty of Medicine and Health Sciences > School of Health Sciences
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Centres > Lifespan Health
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 04 Nov 2022 09:30
Last Modified: 06 Jun 2024 15:21
URI: https://ueaeprints.uea.ac.uk/id/eprint/89594
DOI: 10.1007/s10067-020-04948-1

Actions (login required)

View Item View Item